When was Kenai Therapeutics founded?

Kenai Therapeutics was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Kenai Therapeutics located?

Kenai Therapeutics is headquartered in San Diego, United States.

How many employees does Kenai Therapeutics have?

As of May 31, 2026, the latest employee count at Kenai Therapeutics is 38.

Is Kenai Therapeutics a funded company?

Kenai Therapeutics is a funded company, having raised a total of $89M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2022.

When was the latest funding round of Kenai Therapeutics?

Kenai Therapeutics' latest funding was a $***** Series A round on Feb 29, 2024, with participation from 5 investors. Its primary sector is Cell Therapy. In United States, the Cell Therapy sector has seen $391M in funding in 2026 to date.

Where does Kenai Therapeutics rank among its competitors?

Kenai Therapeutics ranks 5th amongst 116 active competitors, of which 51 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was MRM Health, which secured $3.03M in May, 2026.

Who are the top competitors of Kenai Therapeutics?

Kenai Therapeutics' top competitors include Ventyx Biosciences, Aspen Neuroscience and Cellino. Among them, MRM Health secured the most recent funding round in May, 2026.

Kenai Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of allogeneic cell therapies for neurological diseases. The company utilizes allogeneic induced pluripotent stem cell technology to advance neuron replacement therapeutics. The company's pipeline include RNDP-001 is an iPSC-derived, allogeneic dopamine progenitor cell therapy for the treatment of both idiopathic and inherited forms of Parkinson’s disease.

Key Metrics

Founded Year

2022

Location

San Diego, United States

Stage

Series A

Total Funding

$89M in 3 rounds

Latest Funding Round

Series A, Feb 29, 2024, $*****

Investors

Alaska Permanent Fund & 5 more

Ranked

5^th among 116 active competitors

Employee Count

38 as on May 31, 2026

Similar Companies

Ventyx Biosciences & 125 more

View Kenai Therapeutics' full profile

Kenai Therapeutics has raised a total funding of $89M over 3 rounds. Its first funding round was on 2022. Its latest funding round was a Series A round on Feb 29, 2024 for $*****. 5 investors participated in its latest round. Kenai Therapeutics has 6 institutional investors.

Here is the list of recent funding rounds of Kenai Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 29, 2024	5592183	Series A	4901957	1094663	1194105	5343254
Feb 14, 2023	1486459	Grant (prize money)	9033003	6462890	5265548	State of California
2022	8694	Seed	5380	7927	Saisei Ventures	7851

Access funding benchmarks and valuations. Sign up today!

View details of Kenai Therapeutics's funding rounds and investors

The founders of Kenai Therapeutics are Howard Federoff, Carter Cliff and Jonathan Yeh.

Here are the details of Kenai Therapeutics' key team members:

Howard Federoff: Co-Founder of Kenai Therapeutics and founder of 1 other company.
Carter Cliff: Co-Founder of Kenai Therapeutics and founder of 1 other company.
Jonathan Yeh: Co-Founder & Board Observer of Kenai Therapeutics.

View details of Kenai Therapeutics's Founder profiles and Board Members

Kenai Therapeutics' employee count trend

Kenai Therapeutics has 38 employees as of May 26. Here is Kenai Therapeutics's employee count trend over the years:

Employee count trend for Kenai Therapeutics

Uncover Kenai Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kenai Therapeutics include Ventyx Biosciences, Aspen Neuroscience and Cellino. Here is the list of Top 10 competitors of Kenai Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
2nd	Aspen Neuroscience 2018, San Diego (United States), Series C	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Orbimed, Revelation Partners & 22 others	65/100
3rd	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Khosla Ventures, Humboldt Fund & 7 others	65/100
4th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
5th	Kenai Therapeutics 2022, San Diego (United States), Series A	Developer of allogeneic cell therapies for neurological diseases	$89M	The Column Group, Alaska Permanent Fund & 4 others	60/100
6th	TreeFrog Therapeutics 2018, Talence (France), Series B	Developer of stem cells and organoids using proprietary technology	$84.2M	XAnge, Leonard Green and Partners & 12 others	59/100
7th	MRM Health 2020, Ghent (Belgium), Series B	Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases	$79.2M	DuPont, Ackermans & van Haaren & 11 others	58/100
8th	Trailhead Biosystems 2015, Beachwood (United States), Series B	Developer of cell therapies for the treatment of multiple diseases	$56.7M	MAK Capital, BioEnterprise & 1 others	57/100
9th	Morphocell Technologies 2018, Montreal (Canada), Series A	Developer of an engineered liver for the treatment of liver diseases	$50M	Invest Quebec, CQDM & 2 others	56/100
10th	Clock.bio 2020, Cambridge (United Kingdom), Seed	Developer of treatments for age-related diseases using human pluripotent stem cells	$9.93M	LocalGlobe, Skyworthdigital & 6 others	55/100